StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

Myriad Genetics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Myriad Genetics's total debt was $120.70M at Jun 30, 2026. For fiscal 2025 it was $119.90M, up 202.8% from the year before. The highest annual figure on record is $233.50M in fiscal 2019.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$119.90M+202.8%
FY2024Dec 31, 2024$39.60M+2.9%
FY2023Dec 31, 2023$38.50M–
FY2022Dec 31, 2022$0-100.0%
FY2020Jun 30, 2020$224.40M-3.9%
FY2019Jun 30, 2019$233.50M+2410.8%
FY2018Jun 30, 2018$9.30M-90.6%
FY2017Jun 30, 2017$99.10M–

Quarterly total debt

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$120.70M+103.2%
Q1 FY2026CQ1 2026Mar 31, 2026$120.30M+102.9%
Q4 FY2025CQ4 2025Dec 31, 2025$119.90M+202.8%
Q3 FY2025CQ3 2025Sep 30, 2025$119.50M+206.4%
Q2 FY2025CQ2 2025Jun 30, 2025$59.40M+53.1%
Q1 FY2025CQ1 2025Mar 31, 2025$59.30M+53.2%
Q4 FY2024CQ4 2024Dec 31, 2024$39.60M+2.9%
Q3 FY2024CQ3 2024Sep 30, 2024$39.00M+1.3%
Q2 FY2024CQ2 2024Jun 30, 2024$38.80M+1.0%
Q1 FY2024CQ1 2024Mar 31, 2024$38.70M–
Q4 FY2023CQ4 2023Dec 31, 2023$38.50M-82.8%
Q3 FY2023CQ3 2023Sep 30, 2023$38.50M-82.9%
Q2 FY2023CQ2 2023Jun 30, 2023$38.40M-82.9%
Q4 FY2022CQ4 2022Dec 31, 2022$0-100.0%
Q4 FY2020CQ2 2020Jun 30, 2020$224.40M-3.9%
Q3 FY2020CQ1 2020Mar 31, 2020$225.20M-14.5%
Q2 FY2020CQ4 2019Dec 31, 2019$225.10M-17.6%
Q1 FY2020CQ3 2019Sep 30, 2019$225.00M-12.8%
Q4 FY2019CQ2 2019Jun 30, 2019$233.50M+2410.8%
Q3 FY2019CQ1 2019Mar 31, 2019$263.40M+280.1%
Q2 FY2019CQ4 2018Dec 31, 2018$273.30M+532.6%
Q1 FY2019CQ3 2018Sep 30, 2018$258.00M+160.3%
Q4 FY2018CQ2 2018Jun 30, 2018$9.30M-95.3%
Q3 FY2018CQ1 2018Mar 31, 2018$69.30M–
Q2 FY2018CQ4 2017Dec 31, 2017$43.20M–
Q4 FY2017CQ2 2017Jun 30, 2017$99.10M–
Q1 FY2017CQ3 2016Sep 30, 2016$199.20M–

More Myriad Genetics figures

See a number that looks wrong?